Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 6;7(2):e1390642. doi: 10.1080/2162402X.2017.1390642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 3. — Immunization with citrullinated ENO1 peptides provides an in vivo survival advantage in anti-tumor studies. ENO1 Westerns blots show ENO1 protein expression in cancer cell lines, B16F1 (melanoma), ID8 (Ovarian cancer), TrampC1 (Prostate cancer), Pan02 (Pancreatic ductal adenocarcinoma), LLC/2 (Lung Carcinoma), RTLCL (Lymphoblastoid cell line) and in HeLa cells (A). HLA-DR4 mice were challenged with subcutaneous implant on HLA transgenic B16-DR4 (B), LLC2-DR4 (C), PAN02-DR4 (D) tumor cell lines on day 1. Survival is shown for unimmunized control animals and animals immunized with ENO1 241–260cit₂₅₃ peptide on day 4, 11 and 18. Mice were also challenged with parental B16F1 (E) or LLC2 (F) cell lines before immunization as above.